Probiotics improve various functions of our GI tract, and can help with GI disorders, such as IBS and IBD. However, these “good bacteria” can also prevent cardiovascular disease and boost our immunity, preventing and ameliorating viral and bacterial infections.
- Probiotic Four Part Series
- Health Benefits of Probiotics
- 22) Probiotics are Beneficial in Metabolic Syndrome
- 23) Probiotics Prevent Cardiovascular Disease
- 24) Probiotics Improve Our Gut Health
- Probiotics Beneficially Modify Gut Microbiota
- Probiotics Strengthen the Intestinal Barrier
- Probiotics Prevent and Ameliorate Drug-Induced GI Damage
- Probiotics Ameliorate Gastric Ulcers
- Probiotics Prevent and Treat Diarrhea
- Probiotics Relieve Constipation
- Probiotics Combat IBS
- Probiotics Ameliorate IBD
- Probiotics Ameliorate Necrotizing Enterocolitis
- Probiotics Ameliorate Diverticular Disease
- 25) Probiotics Boost Immunity
- Buy Probiotics
- Further Reading
Probiotic Four Part Series
- Probiotic benefits 1-21 (Part 1)
- Probiotic benefits 22-26 (Part 2)
- Probiotic benefits 27-36 (Part 3)
- Probiotic benefits 37-61 (Part 4)
Health Benefits of Probiotics
22) Probiotics are Beneficial in Metabolic Syndrome
B. animalis ssp. lactis significantly reduced BMI, total cholesterol, low-density lipoprotein and inflammatory cytokines in patients with metabolic syndrome (R).
L. plantarum reduced total cholesterol, LDL-cholesterol, glucose and homocysteine levels in postmenopausal women with metabolic syndrome (R).
23) Probiotics Prevent Cardiovascular Disease
Probiotics and prebiotics have preventative and therapeutic effects on cardiovascular disease due to a reduction in total serum cholesterol, low-density lipoprotein (LDL-cholesterol), and inflammation (R).
Daily supplementation with S. boulardii lowered remnant lipoprotein in hypercholesterolemic adults, a predictive biomarker and potential therapeutic target in the treatment and prevention of coronary artery disease (R).
L. acidophilus consumption lead to 2.4% to 3.2% reduction in blood cholesterol in clinical studies. Since every 1% reduction in serum cholesterol concentration is associated with an estimated 2% to 3% reduction in risk for coronary heart disease, regular intake of L. acidophilus has the potential of reducing the risk for coronary heart disease by 6 to 10% (R).
24) Probiotics Improve Our Gut Health
Probiotics can decrease the number of potentially pathogenic gastrointestinal microorganisms and pathogens, reduce gastrointestinal discomfort, flatulence and bloating, and improve bowel regularity (R).
Administration of L. helveticus to healthy human subjects resulted in a significant increase in butyrate-derivatives-sodium–butyrate-phenylbutyrate-trybutyrine-butyric-acid-butyrate-prodrugs-butyrate-producing-bacteria/” target=”_blank”>butyrate, beneficial for gut homeostasis (R).
Probiotics Beneficially Modify Gut Microbiota
Check individual probiotic posts for more information.
Probiotics Strengthen the Intestinal Barrier
The intestinal barrier separates the contents of the gut from the rest of the body. This barrier prevents the entry of harmful substances such as foreign antigens, toxins and microorganisms. Hyperpermeability of this barrier (“leaky gut”) contributes to the pathogenesis of several gastrointestinal disorders including IBD, Celiac disease and food allergy (R).
In humans, L. rhamnosus protects against disruption of the gastric mucosal barrier (R).
Fermented milk with L. paracasei promotes intestinal epithelial cell growth and intestinal epithelial integrity and strengthens the intestinal barrier against chemical and inflammatory stimuli-induced damage (R).
S. cerevisiae strengthens epithelial barrier function (R). Oral treatment with viable or heat-killed S. cerevisiae strain prevents bacterial translocation, protects intestinal barrier integrity, and stimulates immunity in mice with intestinal obstruction (R).
Probiotics Prevent and Ameliorate Drug-Induced GI Damage
L. acidophilus administered with amoxicillin/clavulanate was associated with a significant decrease in patient complaints of GI side effects and yeast superinfection (R).
Long-term L. rhamnosus supplementation has an influence on the composition of the intestinal microbiota in children, and reduces the frequency of gastrointestinal complaints after antibiotic use, preventing certain bacterial infections for up to 3 years after the trial (R).
L. paracasei therapy prevents antibiotic induced visceral hypersensitivity and restores normal gut permeability in rats (R).
B. animalis ssp. lactis protects against NSAID-induced GI side effects in rats and may prevent more serious GI mucosal damage and/or enhance the recovery rate of the stomach mucosa (R).
Probiotics Ameliorate Gastric Ulcers
Probiotics inhibit the development of acute gastric mucosal lesions and accelerate gastric ulcer healing (R).
Lactobacilli are particularly useful in promoting gastric ulcer healing in rats, when administered as an individual probiotic strain, such as L. rhamnosus, L. gasseri, or L. acidophilus or as a probiotic mixture (R,R,R,R,R,R).
Probiotics Prevent and Treat Diarrhea
Use of probiotics in antibiotic-associated diarrhea decreased the risk of diarrhea by 52%, traveler’s diarrhea by 8%, and acute diarrhea from various causes by 34%. Probiotics were more effective in reducing the risk of acute diarrhea in children 57% versus 26% in adults (R).
Acute Infective Diarrhea:
L. acidophilus and B. bifidum shortened the duration of diarrhea in infants and children (R).
L. rhamnosus administration was associated with significantly lower rates of and symptomatic rotavirus gastroenteritis diarrhea in hospitalized children (R).
L. reuteri decreases the incidence of diarrhea in children (R).
S. boulardii significantly reduces the frequency and duration of acute diarrhea in children (R,R,R,R,R,R,R,R). It also often reduces the length of ECU and hospital stay in acute infectious gastroenteritis in children (R,R).
Treatment with L. rhamnosus reduced the risk of antibiotic-associated diarrhea (AAD) in patients treated with antibiotics from 22.4% to 12.3% (R).
L. helveticus and L. rhamnosus supplementation significantly reduced the duration of antibiotic-associated diarrhea in healthy adults receiving antibiotics (R).
B. animalis spp. lactis together with S. thermophilus reduced the frequency of antibiotic-associated diarrhea (AAD) in infants (R).
Concomitant administration of C. butyricum with antibiotics normalizes the intestinal microbiota, prevents the decrease of Bifidobacteria, and is effective for preventing and treating antibiotic-associated diarrhea in children (R).
Some studies report that S. boulardii is not effective in preventing the development of antibiotic-associated diarrhea (R,R,R,R). However, many studies do, in fact, show that S. boulardii is effective in reducing the risk of antibiotic-associated diarrhea in both children and adults (R,R,R,R,R,R,R).
B. subtilis significantly reduced the incidence of antibiotic-associated diarrhea and prevented nausea, bloating, vomiting and abdominal pain (R).
S. boulardii prevents traveler’s diarrhea, particularly in regions such as North Africa and in the Near-east (R).
Chemo- and Radiotherapy-induced Diarrhea:
Probiotics may have a beneficial effect in prevention of chemo- and radiotherapy-induced diarrhea, where they rarely cause adverse effects (R).
See individual probiotic posts for more information and animal studies.
Probiotics Relieve Constipation
B. breve is effective in diminishing abdominal pain and increasing stool frequency in children with functional constipation (R).
See individual probiotic posts for more information and animal studies.
Probiotics Combat IBS
L. plantarum reduces gas problems and pain in people who suffer from irritable bowel syndrome (R).
Probiotics containing L. plantarum and B. breve in IBS decreased pain by 38% in the probiotic group compared with 18% in the placebo group, and after 28 days, pain was decreased 52% in the probiotic group compared with 11% in the placebo group (R).
L. rhamnosus has been proven to reduce symptoms in children with functional gastrointestinal disorders (R).
B. bifidum significantly improved the pain/discomfort, distension/bloating, urgency and digestive disorder in patients with IBS (R).
Fermented milk containing B. bifidum improves symptoms in patients with functional gastrointestinal disorders (FGID). Abdominal pain, diarrhea, and constipation significantly improved, as did acid-related dyspepsia. Psychological symptoms such as anger and hostility also improved (R).
B. animalis has a beneficial effect on discomfort, bloating and constipation in constipation-predominant IBS patients (R).
B. coagulans decreased bloating, vomiting, diarrhea, abdominal pain and stool frequency and increased the quality of life in patients with the diarrhea predominant irritable bowel syndrome (IBS) (R,R,R,R).
L. brevis improves the quality of life, reduces diarrhea and abdominal pain and increases Bifidobacteria in patients with IBS (R).
In one clinical trial, S. cerevisiae reduced abdominal pain and discomfort in subjects with IBS (R). In another trial, however, S. cerevisiae had no beneficial effect on IBS symptoms and wellbeing. However, it seemed to have some effect in the subgroup with constipation (R).
A combination product designated VSL#3, which contains large quantities of 8 bacterial species, was shown to significantly improve IBS symptoms (R).
Probiotics Ameliorate IBD
B. longum ameliorated ulcerative colitis symptoms in Japanese patients (R).
S. boulardii added to baseline therapy improved intestinal permeability in Chron’s disease (CD) patients, even though complete normalization was not achieved (R). This probiotic also reduced the frequency of bowel movements in CD patients (R).
P. freudenreichii was effective in the treatment of mild to moderate ulcerative colitis in a human pilot study (R).
In Asian studies involving patients with ulcerative colitis, the addition of a B. subtilis probiotic significantly reduced the number of days with bloody stool, lead to complete remission without relapse, and significantly increased the efficacy of mesalazine or sulfasalazine therapy (R).
L. plantarum ameliorates ulcerative colitis in mice via both anti-inflammatory and immunomodulatory activities (R), and decreases the severity of intestinal inflammation in mice with inflammatory bowel disease (IBD) (R).
B. bifidum decreases symptoms of inflammatory bowel disease (IBD) in mice, such as thickened intestinal wall and inflammatory cell infiltration, and decreased inflammatory cytokine production (R).
Other probiotics that were effective in ameliorating colitis in animal models include L. casei (R,R), L. paracasei (R), L. salivarius (R), L. delbrueckii ssp. bulgaricus (R), L. delbrueckii ssp. lactis (R), L. helveticus (R), B. longum (R), B. animalis ssp. lactis (R,R,R), C. butyricum (R,R,R), B. coagulans (R,R), L. brevis (R,R,R), L. fermentum (R,R,R,R), S. boulardii (R), L. lactis (R,R,R,R), S. thermophilus (R), P. freudenreichii (R,R,R), B. subtilisis (R,R,R,R) and S. cerevisiae (R,R).
Check individual probiotic posts for more information.
Probiotics Ameliorate Necrotizing Enterocolitis
Oral supplementation of L. paracasei reduced the clinical progression of necrotizing enterocolitis in infants (R).
Prophylactic L. acidophilus and B. infantis reduced the incidence and mortality of necrotizing enterocolitis (NEC) in infants (R).
B. breve was associated with decreased risk of necrotizing enterocolitis in neonates (R).
Oral administration of B. breve reduces the production of butyric acid in infants, which may be helpful in protecting low birth weight infants from digestive diseases such as necrotizing enterocolitis (R).
However, one study found no benefit in B. breve administration for prevention of necrotising enterocolitis and late-onset sepsis in very preterm infants (R).
B. breve suppresses inflammation, reduces the pathology and increases survival in rats with necrotizing enterocolitis (R).
Probiotics Ameliorate Diverticular Disease
L. paracasei, in association with a high-fiber diet, is effective in reducing abdominal bloating and prolonged abdominal pain in patients with symptomatic uncomplicated diverticular disease (R).
25) Probiotics Boost Immunity
L. paracasei, L. delbrueckii, L. fermentum, L. lactis, L. gasseri, B. longum, B. breve, B. animalis and other probiotics were shown to skew the Th1/Th2 balance toward Th1 (R,R,R,R,R,R,R,R,R,R) in infections and allergies.
Probiotics Combat Infections
L. paracasei prevents common infectious disease (CIDs) in children attending daycare (R).
L. helveticus supplementation significantly shortened the duration and decreased the number of symptoms of upper respiratory tract illness in athletes, and increased their sense of vigor (R).
L. brevis reduces the incidence of influenza in elementary schoolchildren. The improvement is especially pronounced in unvaccinated individuals (R).
S. boulardii enhances the immune response in pediatric acute gastroenteritis (R).
Fermented milk containing L. rhamnosus was efficient in reducing the risk on respiratory tract infections that lasted longer than three days in hospitalized children (R).
Preterm infants treated daily with L. rhamnosus in capsules starting within one week after birth, appear to have significantly lower incidence of respiratory tract infections (RTIs) and rhinovirus-induced episodes in the first 2 months (R).
Consumption of L. rhamnosus reduced the occurrence of respiratory illness in children attending day care centers (R).
Children receiving L. rhamnosus probiotics had fewer days with respiratory symptoms per month than the children in the control group (R).
Capsulated L. rhamnosus was shown to protect hospitalized patients against ventilator-associated pneumonia, mainly when caused by Gram-negative pathogens like Pseudomonas aeruginosa (R).
In cystic fibrosis patients with P. aeruginosa, long-term L. rhamnosus significantly decreased the incidence of pulmonary exacerbations and increased body weight (R).
L. casei significantly lowered the incidence and duration of upper respiratory tract infections (URTIs) in healthy middle-aged office workers (R).
Similarly, in healthy shift workers, L. casei decreased the incidence of gastrointestinal and respiratory common infectious disease (CIDs), increased the time to the first occurrence of CID, and reduced the total number of CIDs in the subgroup of smokers. In the course of CID, the total duration of fever was lower and an increase in leukocyte, neutrophil, and natural killer (NK) cell counts and activity was observed (R).
L. casei also lowered the incidence of common infectious diseases (CIDs) in children (R), and decreased the duration of CID, and especially upper-respiratory-tract infections (URTI) such as rhinopharyngitis in the elderly (R).
In athletic men and women who engaged in endurance-based physical activities in winter, L. casei lowered the proportion of subjects who experienced 1 or more weeks with upper-respiratory-tract infection (URTI) symptoms, and decreased the number of URTI episodes (R).
L. gasseri, B. longum and B. bifidum taken in winter by healthy subjects shortened common cold episodes by almost 2 days and reduced the severity of symptoms (R).
L. acidophilus, B. bifidum and B. animalis plus vitamin C reduced the incidence rate of upper respiratory tract infection, the number of days with symptoms and the absence from preschool in children (R).
A synbiotic containing L. acidophilus, B. infantis, and B. bifidum can provide effective control of respiratory infection and wheezing frequency in children under five years old (R).
L. acidophilus suppressed all of the 74 gram-negative and 16 of gram-positive bacteria found in burn wounds, that can cause burn wound infections (R).
L. fermentum reduced the duration and severity of respiratory illness in highly trained distance runners (R).
L. fermentum reduced the severity of gastrointestinal and respiratory illness symptoms in male but not female cyclists (R).
Oral administration of L. fermentum potentates the immunologic response of an anti-influenza vaccine and may provide enhanced systemic protection by increasing the Th1 response and virus-neutralizing antibodies. The incidence of an influenza-like illness during 5 months after vaccination was decreased in the group that consumed this probiotic (R,R).
B. longum reduces the incidence of influenza and fever in subjects with influenza vaccination (R).
B. longum fed infants showed a trend toward fewer respiratory tract infections (R).
B. longum ssp. infantis triggers the anti-poliovirus response in infants (R).
B. breve significantly inhibited rotavirus multiplication and prevented rotavirus infection in infants (R).
B. animalis ssp. lactis reduces days with cold/flu in young healthy adults (R).
S. boulardii reduces E. coli numbers in children (R).
S. boulardii can treat B. hominis infection in children as efficiently as metronidazole (R).
S. boulardii was effective in treating giardiasis when combined with metronidazole therapy in adult patients (R).
The addition of S. boulardii to metronidazole in amebiasis significantly decreases the duration of (bloody) diarrhea and enhances clearance of cysts in children (R), and decreases the duration of symptoms and cyst passage in adults (R).
Prophylactic S. boulardii supplementation is as effective as nystatin in reducing fungal colonization and invasive fungal infection, more effective in reducing the incidence of clinical sepsis and the number of sepsis attacks and has a favorable effect on feeding intolerance in very low birth weight infants(R).
B. subtilis decreased the frequency of respiratory infections in elderly subjects (R).
B. subtilis inhibits disease transmission in patients with acute non-typhoid Salmonella gastroenteritis (R).
Metabolites of B. subtilis decrease the resistance of urogenital pathogenic microflora to antibiotics in patients with urinary tract infections, resulting in accelerated elimination (R).
Probiotics were effective in treatment and prevention of urogenital infections in women as alternatives or co-treatments. They were effective for treatment and prevention of bacterial vaginosis, prevention of recurrences of candidiasis and urinary tract infections, and clearing human papillomavirus lesions. No study reported significant adverse events related to the probiotic intervention (R).
Probiotic supplementation with vaginal L. rhamnosus is useful in hindering bacteria growth especially after antibiotic therapy (R).
L. rhamnosus vaginal tablets have demonstrated to be a reliable topical effective and safe treatment to reduce the bacterial vaginosis recurrence rate (R).
Daily ingestion yogurt, enriched with L. acidophilus may reduce the episodes of bacterial vaginosis (R). Treatment of patients with bacterial vaginosis with L. acidophilus contributed to the restoration of a normal vaginal environment (R).
L. fermentum and L. plantarum significantly reduced bacterial vaginosis in women (R).
L. crispatus reduces recurrent urinary tract infections in premenopausal women (R).
Cervicovaginal mucus with high L. crispatus concentrations can trap the HIV virus (R).
B. coagulans reduced vaginosis symptoms in women when co-administered with antibiotics (R).
See individual probiotic posts for more information and animal studies.
- Probiotic (Garden of Life) (AMZN) or Probiotics (Garden of Life) (IHERB)
- Probiotics (Swanson 65 billion) (AMZN)
- Probiotics (Now-100 billion)
- Probiotic (VSL-3)
- Probiotics (prescript assist) – great for IBS
- Probiotic (AOR) (AMZN) or Probiotic AOR (IHERB)
- Probiotic – Saccharomyces Boulardii (AMZN) or S Boulardii (IHERB)
For technical information, check individual probiotic chapters:
- B. animalis (B. lactis)
- B. bifidum
- B. breve
- B. coagulans (L. sporogenes)
- B longum
- B. subtilis
- C. butyricum
- L. acidophilus
- L. brevis
- L. casei
- L. crispatus
- L. delbrueckii (L. bulgaricus, L. lactis)
- L. gasseri
- L. helveticus
- L. johnsonii
- L. lactis
- L. paracasei
- L. plantarum
- L. reuteri
- L. rhamnosus
- L. salivarius
- P. freudenreichii
- S. boulardii
- S. cerevisiae
- S. thermophilus